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Abstract 
The study aim was to identify predictive factors for major bleeding in patients receiving the 
novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for 
the treatment of acute symptomatic venous thromboembolism. 
We analyzed data from patients included in the phase III EINSTEIN DVT and EINSTEIN PE 
studies. Factors associated with major bleeding events were assessed with best subset 
variable selection using Cox proportional hazards regression model. Three time windows 
were considered, i.e. the initial 3 weeks, after the third week onwards, and the entire duration 
of the anticoagulant treatment. Model discrimination was estimated using the C-statistic and 
validated internally by bootstrap techniques.  
Major bleeding occurred in 40 (1.0%) of 4130 patients receiving rivaroxaban and in 72 
(1.7%) of 4116 receiving enoxaparin/VKAs, with 44% of the major bleeding events 
occurring in the first 3 weeks of treatment. Significant risk factors for major bleeding were 
older age, black race, low hemoglobin concentrations, active cancer, and antiplatelet or non-
steroidal anti-inflammatory drug therapy. The discrimination of the model for major bleeding 
was high for the first 3 weeks (C-statistic 0.73), from the fourth week onwards (C-statistic 
0.68), and the entire period of anticoagulant treatment (C-statistic 0.74). 
This analysis identified risk factors for major bleeding in patients receiving the novel oral 
anticoagulant rivaroxaban or enoxaparin/VKAs for the treatment of acute venous 
thromboembolism. The prognostic model based on the combination of identified risk factors 
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may be informative to estimate the risk of major bleeding both during the initial and later 
phases of anticoagulation.  
Keywords: hemorrhage, anticoagulants, thrombosis, risk factors, randomized controlled trial 
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Introduction 
Patients receiving anticoagulant treatment for venous thromboembolism (VTE) are at 
increased risk of bleeding events.1,2 Accurate detection of risk factors for major bleeding may 
identify patients who could benefit from more intensive care (e.g. hospitalization) in the acute 
phase and may influence other clinical decisions, such as duration of anticoagulation therapy 
for long-term secondary prevention of VTE (extended vs. shorter-term treatment). 
Combining risk factors for major bleeding during anticoagulation therapy to develop 
predictive scores has been tested in several studies but with heterogeneous results.3–11 
Possible explanations of this inconsistency could include the use of different definitions for 
bleeding, indications for anticoagulation, number and type of predictive variables analyzed, 
trial designs and size, quality of anticoagulation, and quality of statistical model building. 
Different diseases, co-morbid conditions, or co-medications could cause variation in drugs 
metabolism or predispose to bleeding events.12,13 Currently, there are no validated decision 
tools for stratifying the risk of bleeding in patients with VTE who are treated with 
anticoagulants. The recent American College of Chest Physicians (ACCP) guidelines on 
antithrombotic therapies proposed a prediction rule that stratifies patients into low, moderate, 
or high risk of bleeding.14 However, the ACCP rule, as other scores, has not yet been 
validated in clinical practice. In an attempt to externally validate a number of predictive 
scores, Donzé and colleagues found limited discriminative power of all the risk scores 
tested.15 Although conclusions were limited by the small size of the study (515 patients with 
35 major bleeding events), this work underlines the uncertainty around the available scores. 
Similar conclusions were reached in another recent report.16 All bleeding prediction rules 
proposed thus far have been developed from groups of patients receiving vitamin K 
Published in final edited form as: Thromb Haemost. 2016 Jan;115(2):424-32. doi: 10.1160/TH15-06-0474
42 
antagonists (VKAs) only, and there are no data on the risk factors for bleeding in patients 
receiving the novel oral anticoagulants. 
The aim of this study was to identify risk factors for major bleeding events in patients 
receiving rivaroxaban or standard anticoagulant therapy with enoxaparin/VKAs for acute 
VTE who were enrolled in the phase III EINSTEIN DVT and EINSTEIN PE trials.17,18 
Because the risk of bleeding is higher during the first 3 weeks after the start of 
anticoagulation,1 and the relevance of risk factors may differ in the first 3 weeks compared 
with subsequent weeks of anticoagulant treatment, we separately evaluated the impact of the 
identified factors during the initial 3 weeks of treatment, after the third week onwards, and 
for the entire follow-up period of the studies. The results of this study may impact on 
treatment decisions with the ultimate goal of improving safety in patients treated for deep 
vein thrombosis (DVT) or pulmonary embolism (PE).  
Methods 
Study Population and Interventions in the EINSTEIN DVT and EINSTEIN PE trials 
The study design and the characteristics of the patients included in the phase III EINSTEIN 
DVT and EINSTEIN PE studies have been described previously.17-19 Briefly, EINSTEIN 
DVT and EINSTEIN PE were randomized, open-label studies that compared the efficacy and 
safety of rivaroxaban with standard therapy consisting of enoxaparin and a VKA in patients 
with acute, symptomatic and objectively confirmed proximal DVT or PE. 
Patients were assigned to receive oral rivaroxaban 15 mg twice daily for the first 3 weeks, 
followed by 20 mg once daily for an intended 3, 6, or 12 months of treatment. Patients who 
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were assigned to standard therapy received subcutaneous enoxaparin (1.0 mg/kg of body 
weight twice daily) and either warfarin or acenocoumarol, started within 48 hours after 
randomization. Enoxaparin was discontinued when the international normalized ratio (INR) 
was 2.0 or more for 2 consecutive days and the patient had received at least 5 days of 
enoxaparin treatment. The dose of VKA was adjusted to maintain an INR of 2.0 to 3.0. 
In both groups, therapeutic doses of low-molecular-weight heparin, fondaparinux, or 
unfractionated heparin for up to 48 hours before randomization or a single dose of a VKA 
were allowed. Treatment with thrombectomy, a vena cava filter, or a fibrinolytic agent for the 
acute VTE were exclusion criteria, as were any contraindications listed in the labeling of 
enoxaparin, warfarin, or acenocoumarol. Additional exclusion criteria were another 
indication for a VKA; creatinine clearance <30 mL/min; clinically significant liver disease; 
bacterial endocarditis; active bleeding or a high risk of bleeding contraindicating 
anticoagulant treatment; systolic blood pressure >180 mm Hg or diastolic blood pressure 
>110 mm Hg; childbearing potential without proper contraceptive measures, pregnancy, or
breast-feeding; concomitant use of strong cytochrome P450 3A4 inhibitors (e.g., human 
immunodeficiency virus protease inhibitors or systemic ketoconazole) or inducers (e.g., 
rifampicin, carbamazepine, or phenytoin); participation in another experimental 
pharmacotherapeutic program within 30 days before screening; and a life-expectancy of <3 
months. 
Study Outcomes 
The outcome of the present analysis was major bleeding, which was defined as in the original 
studies as clinically overt bleeding associated with a decrease in the hemoglobin level of ≥ 
2.0 g/dL, bleeding that led to the transfusion of ≥ 2 units of red cells, or bleeding that was 
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intracranial or retroperitoneal, or occurring in another critical site, or that contributed to 
death.17,18 Patients with more than one bleeding event were counted only once. 
Study Variables and Statistical Considerations 
The analysis of major bleeding included events that occurred after randomization up to 2 days 
after stopping study treatment. Patients without major bleeding within this time window were 
censored at the last documented study treatment (+ 2 days, not later than the last study visit).  
The appropriate prognostic models were selected with best subset variable selection using 
Cox proportional hazards regression model, i.e. we selected the best model for each number 
of possible predictors and chose the model at which the difference in score statistics between 
the best models of number of predictors k and k+1 is no longer statistically significant at a 
level of 0.05 (interaction terms with p-value>0.10 were omitted too).20 The discrimination of 
the model was assessed by calculating Harrell’s C statistic 21. The C statistic corrected for the 
optimism, or over-fitting, in predictive models was calculated using bootstrapped datasets to 
repeatedly quantify the degree of over-fitting in the model building process.21,22 The 
discrimination of the prognostic model was calculated for the initial 3 weeks of treatment, 
after the third week onwards, and for the entire follow-up period. The choice of 3 weeks was 
motivated by the protocol-mandated reduction in the dose of rivaroxaban after the first 3 
weeks of treatment. 
The following variables were identified as potentially associated with the occurrence of major 
bleeding and included in the full models on which the best subset selection process was 
based: treatment group (rivaroxaban versus enoxaparin/VKAs), gender, active cancer, 
hemoglobin, race (Caucasian, Black, Asian, other which included France where the recording 
of race is legally not allowed), age (and interaction with treatment group), hypertension in 
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medical history, hospitalization for the index event (and interaction with treatment group), 
intensive care admission for the index event, diabetes in the medical history, cardiovascular 
disease in the medical history, chronic heart failure in the medical history, calculated 
creatinine clearance (and interaction with treatment group), platelet count, weight, antiplatelet 
or NSAID medication, index event (PE or DVT only). The model thus checked for 
interactions by testing whether the risk factors had different (separate) associations with 
major bleeding for rivaroxaban and enoxaparin/VKAs. All the above variables were used as 
recorded at baseline except for active cancer where post-baseline diagnosis of cancer was 
also considered. Active cancer at baseline was defined as a diagnosis of cancer that occurred 
within 6 months before enrolment, any treatment for cancer within the previous 6 months, or 
recurrent or metastatic cancer; active cancer during the study was defined as a new diagnosis 
of cancer or recurrence of cancer after randomization.23 Data on continuous variable were 
initially included as a single continuous measurements. The linear relationship between each 
continuous variable and major bleeding was tested by fitting fractional polynomials 24 which 
showed no evidence of nonlinear association between age, hemoglobin, or creatinine 
clearance and major bleeding. When indicated, continuous variables were transformed to 
obtain better parameter estimates and to ensure that the Cox model converged. For this 
reason, the following categories were used: age per 10 years; creatinine clearance (Cockcroft 
and Gault) as normal (i.e. creatinine clearance ≥80 ml/min), mildly (creatinine clearance 50–
79 ml/min), moderately (creatinine clearance 30–49 ml/min), or severely (creatinine 
clearance <30 ml/min) impaired.25 The renal function categories were included in the Cox 
proportional-hazards models as single covariates. For weight,  the best fit was obtained with 
the linear term weight per 100 kg and the power function 1/(weight per 100)2. . Missing data 
for weight, height, calculated creatinine clearance, and hemoglobin were estimated with 
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multiple imputation technique based on a Markov chain Monte Carlo approach.26 We decided 
a priori to exclude patients with clinically overt bleeding associated with a decrease in 
hemoglobin level of ≥ 2.0 g/dL when the bleeding event occurred within 24 hours of study 
inclusion. This was done in the attempt not to overestimate the prognostic weight of 
hemoglobin concentrations, which in these cases could represent a sign of a hidden bleeding 
event becoming symptomatic on the day of inclusion rather than a real marker of the event. 
For this reason, one subject was excluded from all models because of a major bleeding 
(hemoglobin drop > 2g/dL)  and a low hemoglobin value (9.7 g/dL) on the day of 
randomization. 
Firth’s penalized maximum likelihood estimation was performed in the final Cox 
proportional hazards models to reduce bias in the parameter estimates.  Based on the 
respective final best Cox proportional hazard model the linear predictor Ziβ can be calculated 
for a subject i (in the study or a future subject with given covariate vector Zi) to predict the  
cumulative major bleeding rate at time point t (i.e. at day 21, at day 180) as follows: 
F(t)=1-S(t)=1 - S0 (t)exp(Zβ) )∙where t = 21, 180, 180 + 21= 201 days respectively. 
Prediction of major bleeding in the current population by other bleeding scores 3,5-6,9,11-12 was 
done by calculating the individual score per patient , categorizing the score into 3 levels 
(e.g.low, intermediate and high risk), fitting Cox proportional hazard models and calculating 
Harrell’s C statistic.  
The statistical analyses were performed with SAS version 9.2 and by STATA 11.2. 
Results 
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The EINSTEIN DVT and EINSTEIN PE studies randomized 3449 and 4832 patients, 
respectively (8281 in total), 99% of whom contributed to the analyses. For the present 
analysis, only patients who took at least one dose of study medication were included (safety 
population, N = 8245). For the analysis of all major bleeding events, we considered 8245 
patients up to 3 weeks, and up to the end of actual study treatment. All 8060 patients who 
were not censored/did not have an event within the first 3 weeks were included in the analysis 
of major bleeding after the first 3 weeks of treatment. 
The characteristics of the study population are reported in Table 1. In the enoxaparin/VKAs 
group, the median duration of enoxaparin treatment was 7.4 days (interquartile range [IQR] 
5.8 to 10.1). Overall, the INR was in the therapeutic range (2.0 to 3.0) for a mean of 62% of 
the time, above 3.0 for 16% of the time, and below 2.0 for 22% of the time. The time in 
therapeutic range varied from 56% (month 1) to 66% (months 7 to 12). Patients in the 
enoxaparin/VKAs group received anticoagulant treatment for a median of 182 days (IQR 178 
to 266 days). Rivaroxaban was administered for a median of 183 days (IQR 179 to 269 days) 
and adherence to rivaroxaban was > 80% in 93% of patients. 
Overall, major bleeding occurred in 40 (1.0%) of 4130 patients receiving rivaroxaban and in 
72 (1.7%) of 4116 patients receiving enoxaparin/VKAs. Of these bleeding events, 49 
occurred in the first 3 weeks (44%), 16 (0.3%) in the rivaroxaban group and 33 (0.7%) in the 
enoxaparin/VKAs group. Table 2 describes the major bleeding events that occurred during 
the study. 
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Events During the First 3 Weeks of Treatment 
Of 8246 patients, 8219 (99.7%) contributed to the analyses for the first 3 weeks of treatment. 
Table 3 shows the results of the multivariable analysis of the variables associated with major 
bleeding during the first 3 weeks of anticoagulant therapy. 
The use of rivaroxaban was associated with a lower risk and enoxaparin/VKAs with a higher 
risk of major bleeding (HR 0.43; 95% CI 0.23 to 0.80). The presence of active cancer and 
black race were associated with a significantly higher risk of major bleeding (HR 3.47; 95% 
CI 1.79 to 6.70, and HR 3.26; 95% CI 1.15 to 9.23, respectively). 
There was an inverse relationship between the risk of bleeding and hemoglobin 
concentrations (HR per each mg/dL 0.72; 95% CI 0.62 to 0.84) or renal function (HR 0.62; 
95% CI 0.42 to 0.91). Antiplatelet and/or NSAID use doubled the risk (HR 2.07; 95% CI 
1.12 to 3.82). The risk of major bleeding seemed higher at low weight (below 50 kg)  and it 
was numerically driven by the major bleeding in the enoxaparin/VKA treatment group19. (see 
online Graph 1).There was no statistical evidence that the association between major bleeding 
and age, creatinine clearance categories, or weight was different between treatment groups (p 
for interaction > 0.10). The prognostic model including all variables (Table 3) had a high 
discrimination, as shown by a Harrel's C statistic of 0.79 (0.73 after correcting for selection 
and estimating optimism by the bootstrap procedure). In a hypothetical Caucasian patient 
with no active cancer, no antiplatelet or NSAIDs medication, hemoglobin of 10 mg/dL, 
weight of 50 kg, creatinine clearance of 30-49 mL/min, the predicted probability of a major 
bleeding event at 21 days was 2.7% when receiving enoxaparin/VKAs and 1.2% if she was 
on rivaroxaban (See Online Table).  
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Events After The first 3 Weeks of Treatment 
Table 4 shows the variables associated with major bleeding after the first 3 weeks of 
anticoagulant therapy. The use of rivaroxaban was associated with a lower risk and 
enoxaparin with a higher risk of major bleeding (HR 0.60; 95% CI 0.37 to 1.00). The 
incidence of major bleeding was increased by 45% every 10 years of age (HR 1.45; 95% CI 
1.22 to 1.74). There was a significant inverse association between hemoglobin and risk of 
bleeding (HR per each mg/dL 0.66; 95 % CI 0.53 to 0.81) and some suggestion that this 
relationship was different between males and females (p for interaction= 0.0663, see online Graph 
2). Male and female patients had similar risk of major bleeding if hemoglobin was 12 mg/dL 
or higher (HR 1.40 at 12 mg/dL; 95% CI: 0.78 to 2.52). Compared to Caucasian, black race 
carried an almost four fold increased risk (HR 3.93; 95% CI 1.42 to 10.86). 
There was no statistical evidence that the association between major bleeding and age, 
creatinine clearance categories, or weight was different between treatment groups (p for 
interaction > 0.05). The Harrel's C statistic of the prediction model (Table 4) was 0.74 (0.68 after 
correcting for selection and estimating optimism by the bootstrap procedure). In a 
hypothetical Caucasian female patient with no cardiovascular disease in medical history, 
hemoglobin of 10 mg/dL, the predicted probability of a major bleeding event at 201 days was 
1.6% if she was receiving enoxaparin/VKAs and 1.0% if on rivaroxaban (See web link). 
Events During the Entire Treatment Period 
Table 5 shows the variables associated with major bleeding during the entire treatment 
period. Active cancer, black race, and use of antiplatelet or NSAIDs were all independently 
associated with the occurrence of major bleeding events. A lower risk was observed with 
Rivaroxaban and a higher risk with enoxaparin/VKAs (HR 0.50; 95% CI 0.34 to 0.74). There 
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was an inverse relationship between hemoglobin concentrations and major bleeding (HR per 
each mg/dL 0.65; 95% CI 0.56 to 0.75), with some statistical evidence that the effect of 
hemoglobin was different between males and females (p for interaction= 0.0041, see online Graph 
3). The risk of major bleeding increased by 33% every 10 years of age (HR 1.33; 95% CI 
1.17 to 1.52). There was a suggestion that the risk of major bleeding is higher at low weight 
(below 50 kg) and numerically driven by the major bleeding in the enoxaparin/VKAs 
treatment group 19 (see online Graph 4). The Harrel's C statistic of the prediction model 
(Table 5) was 0.77 (0.74 after correcting for selection and estimating optimism by the 
bootstrap procedure). In a hypothetical 60 year old female patient with no active cancer, no 
antiplatelet or NSAIDs medication, weight of 50 kg, hemoglobin of 10 mg/dL, no index PE,  
the predicted probability of a major bleeding event at 180 days (6 months) was 3.8%, if she 
was on enoxaparin/VKAs and 1.9% if on rivaroxaban (See web link). 
Discussion 
This study identified risk factors for major bleeding in patients receiving the novel oral direct 
factor Xa inhibitor rivaroxaban or enoxaparin/VKAs for the treatment of acute VTE. The 
combination of these risk factors into a prognostic model showed a high discrimination both 
during the initial and subsequent phases of the anticoagulation therapy.  
The incidence of bleeding events differs between the initial phase of treatment and the 
subsequent phase, with the risk being higher in the first weeks of anticoagulation.1 With the 
risk of bleeding changing over time, the importance of risk factors may vary depending on 
the timing since the start of anticoagulant treatment. Therefore, the discriminative ability of 
the model was separately analyzed for the first 3 weeks of anticoagulant treatment, after the 
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third week, and for the entire follow-up period. A number of variables differed between the 
three models, with some being associated with major bleeding both in the initial and 
subsequent phase of anticoagulation and others being apparently relevant only in the short-
term phase or in the long-term phase. As an example the concomitant use of antiplatelet or 
NSAIDs was associated with a higher risk of bleeding especially during the first weeks of 
anticoagulation. These results confirm previous observations 27 and suggest that in patients 
with a clinical indication for long-term NSAID or additional antiplatelet treatment, a dose 
reduction or interruption of these agents should be considered whenever possible. Another 
example was body weight, which was significantly associated with a higher risk of major 
bleeding only during the first 3 weeks. Black race emerged as a significant predictor of events 
in all treatment phases considered. The increased risk in black versus other races was largely 
driven by a higher incidence of major gastrointestinal bleeding in the enoxaparin/VKAs 
group (3.6% in Black race patients vs. 0.4% in Caucasian patients). Previous research did not 
report race as predictor, so that we cannot exclude that black race is a confounding indicator, 
highly associated with an unknown predictor that we did not consider in our models.  
The development of a model to estimate the risk of major bleeding in patients receiving 
anticoagulant therapy for VTE has been the objective of intensive investigation.3-11 One of 
the most studied predictive scores is the Outpatient Bleeding Risk Index (OBRI), which was 
retrospectively derived from a group of 627 hospitalized patients, of whom only 103 (17%) 
received treatment for VTE.5,6 The OBRI score was externally validated by Wells and 
colleagues, who suggested a good discrimination between low- and moderate-risk patients, 
although results for the high-risk group were inconclusive because this subgroup was 
underrepresented in the study.28 Most risk scoring systems are limited by a retrospective 
study design7,9,12,29 and/or lack of external or prospective validation.9,29 In a recent cohort of 
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515 internal medicine patients receiving VKAs, Donzé and colleagues prospectively 
validated seven predictive scores.15 Their findings suggested poor discrimination of all 
scores, as indicated by calculated C statistic values between 0.54 and 0.61, with no significant 
differences between the scores. The authors found that the performance of the scores was not 
statistically better than the physicians’ subjective risk assessment, and only the ATRIA score 
performed slightly better than expected by chance alone. Similar results were obtained in two 
other studies comparing the clinical performance of several bleeding risk tools.16, 30,31 
In the current study, the C statistic of the model varied from 0.74 for the entire period of 
anticoagulation and the first 3 weeks to 0.68 from the fourth week onwards. These C statistic 
values indicate good performance and seem to compare favorably with other models. Table 6 
depicts results of the current prediction model and of the external validation of previously 
published scores in terms of the Harrel's C statistics with 95% confidence intervals. The 
EINSTEIN DVT and EINSTEIN PE study populations were used in all these analyses. 
However, the indirectness of the comparison with differences in study population and type of 
variables included in the model limits conclusions and external validation of our prediction 
score is desired. 
 
Limitations 
The major limitation of this study is related to the applicability of the model, given that in a 
phase III trial patients with contraindications to anticoagulant therapy are excluded, thus 
making the present findings not generalizable to the whole population of patients with VTE. 
Some factors significantly associated with bleeding in previous scores, such as hepatic 
failure, active gastroduodenal ulcer, gastrointestinal bleeding, severe renal insufficiency, and 
alcohol abuse were exclusion criteria for the EINSTEIN studies. As a consequence, we were 
Published in final edited form as: Thromb Haemost. 2016 Jan;115(2):424-32. doi: 10.1160/TH15-06-0474
53 
not able to assess the importance of these factors in our risk score. In the external validation 
of other bleeding risk scores such as the OBRI or HAS-BLED, we had to appoint a "0" value 
representing the absence of such risk factor, which may have affected the calculated statistics, 
so that the descriptive comparison between any of the models displayed in Table 6 should be 
considered exploratory.  The overall incidence of major bleeding in this study was 1.3%, 
which compares well with the rates reported in other randomized clinical trials,1,32 but 
appears to be slightly lower than that reported in observational cohort studies.3,4,7,13,15 
Although our analyses included a large number of patients, the total number of major 
bleeding events is still rather small and bootstrapping internal validation might only mitigate 
the effect of low statistical power. External validation of these findings in an independent and 
sufficiently large dataset is warranted.  
We did not have information about genetic risk factors for major bleeding such as CYP 2C9 
mutations, although the value of genetic testing for the prediction of bleeding risk is still 
controversial and not widely used in clinical practice.1,33 
Strengths 
This is one of the first studies that attempted to identify bleeding risk factors for one of the 
novel oral anticoagulants, namely the factor Xa inhibitor rivaroxaban. When possible, the 
analysis did not merely consider the presence or absence of risk factors, but rather took into 
account their severity (e.g. platelet count, renal function, age), which may influence the risk 
of bleeding. The current analysis identified a small number of risk factors readily available 
from the clinical medical history or routinely tested in patients with VTE which could be 
used to calculate the risk of major bleeding in an individual patient i at a time t by an user-
friendly online tool (See Online Table). Finally, major strengths of the study are the relatively 
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large sample size, the completeness of the dataset, and the adjudication of all bleeding end 
points, including major bleeding by an external blinded independent committee, thus 
reducing the risk of assessment bias. 
We identified risk factors for major bleeding in patients receiving rivaroxaban for the 
treatment of acute VTE. The bleeding prognostic model based on the combination of 
identified risk factors showed high discrimination. Future studies are warranted to validate 
this model and to confirm an approach stratified by the time elapsed after the start of 
anticoagulation. 
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Table 1. Demographic Data and Baseline Characteristics 
 
Rivaroxaban 
(N=4130) 
Enoxaparin/VKA 
(N=4116) 
Total 
(N=8246) 
Age at enrollment, years, mean (SD) 57.0 (17.0) 57.0 (16.8) 57.0 (16.9) 
<65 years, n (%) 2592 (62.8) 2579 (62.7) 5171 (62.7) 
65 to 75 years, n (%) 883 (21.4) 913 (22.2) 1796 (21.8) 
>75 years, n (%) 655 (15.9) 624 (15.2) 1279 (15.5) 
Sex, n (%)    
Males  2294 (55.5) 2206 (53.6) 4500 (54.6) 
Females 1836 (44.5) 1910 (46.4) 3746 (45.4) 
Race, n (%)    
Caucasian 2898 (70.2) 2896 (70.4) 5794 (70.3) 
Black 104 (2.5) 111 (2.7) 215 (2.6) 
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Rivaroxaban 
(N=4130) 
Enoxaparin/VKA 
(N=4116) 
Total 
(N=8246) 
Asian 388 (9.4) 371 (9.0) 759 (9.2) 
Other 740 (17.9) 738 (17.9) 1478 (17.9) 
Body mass index (kg/m2) 
Mean (SD) 28.1 (5.7) 28.1 (5.6) 28.1 (5.7) 
<30 kg/m², n (%) 2860 (69.2) 2857 (69.4) 5717 (69.3) 
≥30 kg/m², n (%) 1248 (30.2) 1235 (30.0) 2483 (30.1) 
Creatinine clearance* 
Mean (SD) 101.8 (44.3) 101.8 (41.6) 101.8 (42.9) 
≥80 mL/min 2757 (66.8) 2786 (67.7) 5543 (67.2) 
50 to <80 mL/min 1027 (24.9) 999 (24.3) 2026 (24.6) 
<50 mL/min 329 (8.0) 321 (7.8) 650 (7.9) 
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Rivaroxaban 
(N=4130) 
Enoxaparin/VKA 
(N=4116) 
Total 
(N=8246) 
Index event, n (%)    
Only DVT 1688 (40.9) 1687 (41.0) 3375 (40.9) 
PE with DVT 615 (14.9) 595 (14.5) 1210 (14.7) 
PE without DVT 1787 (43.3) 1798 (43.7) 3585 (43.5) 
No confirmed index event 40 (1.0) 36 (0.9) 76 (0.9) 
Cause of DVT/PE, n (%)    
Spontaneous DVT/PE 2605 (63.1) 2628 (63.8) 5233 (63.5) 
Secondary DVT/PE 1525 (36.9) 1488 (36.2) 3013 (36.5) 
Recent surgery or trauma 752 (18.2) 726 (17.6) 1478 (17.9) 
Immobilization 648 (15.7) 636 (15.5) 1284 (15.6) 
Use of estrogen-containing drugs 345 (8.4) 337 (8.2) 682 (8.3) 
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Rivaroxaban 
(N=4130) 
Enoxaparin/VKA 
(N=4116) 
Total 
(N=8246) 
Puerperium 12 (0.3) 15 (0.4) 27 (0.3) 
Active cancer  232 (5.6) 196 (4.8) 428 (5.2) 
Cancer status, n (%) 
No active cancer  3814 (92.3) 3838 (93.2) 7652 (92.8) 
Active cancer at baseline 232 (5.6) 196 (4.8) 428 (5.2) 
Cancer reported as adverse event during the study 84 (2.0) 82 (2.0) 166 (2.0) 
Diabetes, n (%) 
No 3719 (90.0) 3692 (89.7) 7411 (89.9) 
Yes 411 (10.0) 424 (10.3) 835 (10.1) 
Chronic heart failure, n (%) 
No 4057 (98.2) 4064 (98.7) 8121 (98.5) 
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Rivaroxaban 
(N=4130) 
Enoxaparin/VKA 
(N=4116) 
Total 
(N=8246) 
Yes 73 (1.8) 52 (1.3) 125 (1.5) 
Cardiovascular disease, n (%) 
No 3787 (91.7) 3807 (92.5) 7594 (92.1) 
Yes 343 (8.3) 309 (7.5) 652 (7.9) 
Previous episode(s) of DVT/PE, n (%) 
Previous episode(s) of DVT/PE 788 (19.1) 813 (19.8) 1601 (19.4) 
No previous episode(s) of DVT/PE 3342 (80.9) 3303 (80.2) 6645 (80.6) 
Pre-randomization LMWH treatment taken, n (%) 
No pre-randomization treatment 645 (15.6) 688 (16.7) 1333 (16.2) 
Pre-randomization treatment given 3485 (84.4) 3428 (83.3) 6913 (83.8) 
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Rivaroxaban 
(N=4130) 
Enoxaparin/VKA 
(N=4116) 
Total 
(N=8246) 
Duration of (LMWH/heparin/fondaparinux) 
pre-medication (days) 
Median 1.00 1.00 1.00 
Min 0.5 0.5 0.5 
Max 37.0 6.8 37.0 
Hemoglobin at baseline (g/dL), n (%) 
Mean (SD) 13.5 (1.8) 13.5 (1.7) 13.5 (1.7) 
≤10 g/dL 148 (3.6) 155 (3.8) 303 (3.7) 
Females: 10 to <12 g/dL, Males: 10 to <13 g/dL 768 (18.6) 725 (17.6) 1493 (18.1) 
Females: ≥12 g/dL, Males: ≥13 g/dL 3205 (77.6) 3219 (78.2) 6424 (77.9) 
Platelet count at baseline, n (%) 
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Rivaroxaban 
(N=4130) 
Enoxaparin/VKA 
(N=4116) 
Total 
(N=8246) 
Median (Q1, Q3)† 229.0 (187.0, 282.0) 229.0 (187.0, 284.0) 229.0 (187.0, 283.0) 
≤100,000/µL 53 (1.3) 31 (0.8) 84 (1.0) 
100,000 to ≤150000/µL 315 (7.6) 349 (8.5) 664 (8.1) 
>150000/µL 3742 (90.6) 3712 (90.2) 7454 (90.4) 
Hospitalization for index event, n (%)    
Hospitalization 3027 (73.5) 3066 (74.6) 6093 (74.0) 
No hospitalization 1093 (26.5) 1045 (25.4) 2138 (26.0) 
 
* Creatinine clearance levels were calculated using the equation of Cockroft and Gault, using the last value up to the day of randomization. 
† Q1 = 25th percentile, Q3 = 75th percentile. AE indicates adverse event; LMWH, low-molecular-weight heparin; DVT, deep vein thrombosis; PE, 
pulmonary embolism; SD, standard deviation; and VKA, vitamin K antagonist. 
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Table 2. Incidence of Major Bleeding in the Safety Population 
Bleeding Events Rivaroxaban 
N=4130 (100) 
Enoxaparin/VKA 
N=4116 (100) 
Major bleeding, n (%) 40 (1.0) 72 (1.7) 
Fatal bleeding 3 (<0.1) 8 (0.2) 
Intracranial 2 (<0.1) 4 (<0.1) 
Retroperitoneal 0 1 (<0.1) 
Gastrointestinal 1 (<0.1) 2 (<0.1) 
Thorax 0 1 (<0.1) 
Non-fatal critical organ bleeding 10 (0.2) 27 ( 0.7) 
Intracranial 3 (<0.1) 9 (0.2) 
Retroperitoneal 1 (<0.1) 7 (0.2) 
Intraocular 3 (<0.1) 2 (<0.1) 
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Bleeding Events Rivaroxaban 
N=4130 (100) 
Enoxaparin/VKA 
N=4116 (100) 
Pericardial 0 2 ( <0.1) 
Intra-articular 0 4 ( <0.1) 
Adrenal gland 1 (<0.1) 0 
Pulmonary 1 (<0.1) 0 
Abdominal 1 (<0.1) 2 <0.1) 
Vitreous body 0 1 (<0.1) 
Non-fatal non-critical organ bleeding (fall in Hb ≥2 g/dl and/or transfusions ≥2 units) 27 (0.7) 36 (0.9) 
Surgical site 0 3 (<0.1) 
Skin (other than injection site) 1 (<0.1) 4 (<0.1) 
Urogenital 2 (<0.1) 4 (<0.1) 
Gastrointestinal 12 (0.3) 20 (0.5) 
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Bleeding Events Rivaroxaban 
N=4130 (100) 
Enoxaparin/VKA 
N=4116 (100) 
Nasal 1 (<0.1) 0 
Rectal 2 (<0.1) 3 (<0.1) 
Injection/blood sampling site 0 1 (<0.1) 
Uterus 7 (0.2) 0 
Pulmonary 1 (<0.1) 0 
Intramuscular 1 (<0.1) 2 (<0.1) 
Other specified major bleeding 0 1 (<0.1) 
Rectal 0 1 (<0.1) 
Hb indicates hemoglobin; and VKA, vitamin K antagonist 
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Table 3. Risk Factors for Major Bleeding Events in the First 3 Weeks of Treatment 
Covariate Hazard Ratio (95% CI) 
Anticoagulant Treatment 
Rivaroxaban vs. Enoxaparin/VKA 0.43 (0.23 to 0.80) 
Active cancer 3.47 (1.79 to 6.70) 
Hemoglobin, mg/dl 0.72  (0.62 to 0.84) 
Race 
Black vs. Caucasian 
Asian vs. Caucasian 
Other vs. Caucasian 
3.26 (1.15 to 9.23) 
1.01 (0.38 to 2.71) 
1.78 (0.87 to 3.65) 
Antiplatelet and/or NSAID concomitant medication at baseline* 2.07 (1.12 to 3.82) 
Weight, per 100 kg 18.56 (1.81 to 190.6) 
Weight in 1/(Weight per100)2 1.69 (1.01 to 2.80) 
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Creatinine clearance † 0.62 (0.42 to 0.91) 
* vs. no such concomitant medication; †Renal function was categorized as normal (i.e. CrCl ≥80 ml/min; score: 3), or with impairment that was
mild (CrCl 50–79 ml/min; score: 2), moderate (CrCl 30–49 ml/min; score: 1), or severe (CrCl <30 ml/min; score: 0). CI indicates confidence 
interval; NSAIDs, non-steroidal anti-inflammatory drugs; and VKA, vitamin K antagonist. 
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Table 4. Risk Factors for Major Bleeding Events After the First 3 Weeks of Treatment 
Covariate Hazard Ratio (95% CI) 
Anticoagulant Treatment 
Rivaroxaban vs. Enoxaparin/VKA 0.60 (0.37 to 1.00) 
Age, per 10 years 1.45 (1.22 to 1.74) 
Hemoglobin, mg/dl 0.66 (0.53 to 0.81) 
Male sex if hemoglobin 12 mg/dl 1.40 (0.78 to 2.52) 
Hemoglobin among males, mg/dl 1.31 (0.98 to 1.74) 
Race 
Black vs. Caucasian 
Asian vs. Caucasian 
Other vs. Caucasian 
3.93 (1.42 to 10.86) 
1.11 (0.44 to 2.82) 
1.74 (0.98 to 3.07) 
Cardiovascular disease in the medical history 1.74 (0.91 to 3.33) 
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CI indicates confidence interval and VKA, vitamin K antagonist 
Table 5. Risk Factors for Major Bleeding Events in the Entire Study Treatment Period 
Covariate Hazard Ratio (95% CI) 
Anticoagulant Treatment 
Rivaroxaban vs. Enoxaparin/VKA 0.50 (0.34 to 0.74) 
Active cancer 2.49 (1.54 to 4.03) 
Hemoglobin, mg/dl 0.65  (0.56 to 0.75) 
Male sex if hemoglobin 12 mg/dl 1.05 (0.65 to 1.71) 
Hemoglobin among males, mg/dL 1.37  (1.11 to 1.70) 
Race 
Black vs. Caucasian 
Asian vs. Caucasian 
Other vs. Caucasian 
2.84 (1.23 to 6.55) 
1.03 (0.51 to 2.07) 
1.54 (0.97 to 2.44) 
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Antiplatelet and/or NSAIDs concomitant medication at baseline* 1.75 (1.16 to 2.64) 
Age, per 10 years 1.33 (1.17 to 1.52) 
Weight, per 100 kg 3.24 (0.45 to 23.26) 
Weight in 1/(Weight per100)2 1.48 (0.99 to 2.21) 
Index PE (yes vs. no) 1.48 (0.97 to 2.27) 
* vs. no such concomitant medication; CI indicates confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs; and VKA, vitamin K
antagonist. 
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Table 6. Prediction of major bleeding in the current population by other bleeding scores 
Bleeding index/score First 3 Weeks of Treatment Fourth week onwards Entire Study Treatment Period 
Current Prediction model 0.73 (0.65 to 0.81) 0.68 (0.60 to 0.76) 0.74 (0.68 to 0.80) 
Outpatient bleeding risk index score5,6 0.54 (0.49 to 0.58) 0.53 (0.49 to 0.56) 0.53 (0.50 to 0.56) 
Kuijer score9 0.64 (0.57 to 0.72) 0.64 (0.60 to 0.68) 0.64 (0.60 to 0.68) 
HEMORR2HAGES score12 0.64 (0.57 to 0.72) 0.66 (0.59 to 0.72) 0.65 (0.60 to 0.70) 
HAS-BLED score11 0.58 (0.51 to 0.64) 0.62 (0.56 to 0.68) 0.59 (0.55 to 0.64) 
RIETE score3 0.63 (0.60 to 0.66) 0.57 (0.52 to 0.62) 0.60 (0.57 to 0.63) 
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The table depicts results of the current prediction model and of external validations of previously published scores categorized into 3 levels (e.g. 
low, intermediate and high risk) in terms of the Harrel's C statistics with 95% confidence intervals.The EINSTEIN DVT and EINSTEIN PE study 
populations were used in all analyses. 
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